Carteolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Carteolol
Therapeutic Class: Beta-Adrenergic Blocker
Subclass: Non-selective Beta-Adrenergic Receptor Antagonist (Ophthalmic)
Speciality: Ophthalmology
Schedule (India): H
Route(s): Ophthalmic (topical)
Formulations Available in India:
- Ophthalmic solution (eye drops): 1% w/v
- Ophthalmic solution (eye drops): 2% w/v (limited availability)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Primary Open-Angle Glaucoma
| Parameter | Recommendation |
| Starting dose | 1 drop of 1% solution into affected eye(s) twice daily |
| Titration | If inadequate IOP reduction after 4 weeks, consider combination therapy rather than increasing concentration |
| Usual maintenance dose | 1 drop of 1% solution twice daily |
| Maximum dose | 1 drop twice daily; 2% solution may be used in resistant cases (specialist decision) |
Clinical notes:
- Onset of action: within 30 minutes; peak IOP-lowering effect at 2–3 hours
- Duration of effect: approximately 12 hours
- Possesses intrinsic sympathomimetic activity (ISA), potentially causing fewer cardiovascular side effects compared to timolol
- Advise punctal occlusion for 1–2 minutes after instillation to minimize systemic absorption
- If monotherapy inadequate, combine with prostaglandin analogue, alpha-agonist, or carbonic anhydrase inhibitor
2. Ocular Hypertension
| Parameter | Recommendation |
| Starting dose | 1 drop of 1% solution into affected eye(s) twice daily |
| Titration | Assess response at 4 weeks; add adjunctive therapy if target IOP not achieved |
| Usual maintenance dose | 1 drop of 1% solution twice daily |
| Maximum dose | 1 drop twice daily |
Clinical notes:
- Expected IOP reduction: 20–25% from baseline
- Reassess need for continued therapy periodically
Secondary Indications – Adults (Off-label, if any)
Not applicable. No documented off-label indications with established evidence in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
âš Use only under paediatric ophthalmologist supervision. Safety and efficacy not well established in children.
Paediatric Glaucoma (including congenital and juvenile glaucoma)
| Age Group | Dosing | Clinical Notes |
| ≥2 years | Starting dose: 1 drop of 1% solution once daily | Initiate with once-daily dosing |
| Titration: May increase to twice daily if inadequate response | ||
| Usual maintenance: 1 drop once or twice daily | ||
| Maximum: 1 drop twice daily |
Mandatory safety monitoring:
- Monitor for systemic beta-blockade effects at each visit: bradycardia, hypotension, bronchospasm, lethargy
- In neonates and infants: watch for sleep apnoea, hypotonia, poor feeding
- Punctal occlusion essential (1–2 minutes) to minimize systemic absorption
- Baseline and periodic heart rate and respiratory assessment recommended
Age restriction: Not recommended below 2 years of age except under specialist supervision with close monitoring for systemic effects.
Secondary Indications – Paediatrics (Off-label, if any)
Not applicable. No documented off-label paediatric indications in Indian practice.
RENAL ADJUSTMENT
No dose adjustment required for topical ophthalmic use. Systemic absorption is minimal with proper instillation technique (punctal occlusion).
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | No dose adjustment required; monitor for systemic effects |
| Severe impairment | Use with caution; monitor for signs of systemic beta-blockade if significant systemic absorption suspected |
CONTRAINDICATIONS
- Bronchial asthma (current or history of bronchospasm)
- Severe chronic obstructive pulmonary disease (COPD)
- Sinus bradycardia (<50 bpm)
- Second-degree or third-degree atrioventricular block (without pacemaker)
- Sick sinus syndrome
- Cardiogenic shock
- Decompensated heart failure
- Hypersensitivity to carteolol, other beta-blockers, or any formulation component
- Concurrent intravenous verapamil or diltiazem
CAUTIONS
- Mild to moderate asthma or COPD: Risk of bronchospasm even with topical use; avoid if possible
- Diabetes mellitus: May mask hypoglycaemia warning symptoms (tachycardia, tremor)
- Thyrotoxicosis: May mask clinical signs including tachycardia
- Myasthenia gravis: May exacerbate muscle weakness
- Peripheral vascular disease: May worsen symptoms
- First-degree AV block: Monitor for progression
- Concurrent systemic beta-blockers: Additive beta-blockade effects
- History of atopy or anaphylaxis: May reduce responsiveness to adrenaline
- Abrupt discontinuation: Risk of rebound IOP elevation; taper if possible
- Contact lens wearers: Preservatives may be absorbed by soft lenses; remove before instillation and wait 15 minutes before reinsertion
PREGNANCY
| Parameter | Recommendation |
| Overall safety | Limited human data; animal studies do not indicate major teratogenicity; use only if benefit clearly outweighs risk |
| Preferred alternatives | Brimonidine (avoid near term), prostaglandin analogues (with obstetric consultation) |
| When may be used | If IOP control critical and alternatives unsuitable; specialist input recommended |
| Monitoring | Fetal heart rate monitoring in late pregnancy if used chronically; neonatal observation for beta-blockade signs at delivery |
LACTATION
| Parameter | Recommendation |
| Compatibility | Likely compatible if used topically with punctal occlusion |
| Preferred alternatives | Prostaglandin analogues, brimonidine (avoid in first few months postpartum) |
| Expected milk levels | Low (minimal systemic absorption with proper technique) |
| Infant monitoring | Heart rate, feeding pattern, alertness; watch for bradycardia, lethargy, poor feeding |
ELDERLY
| Parameter | Recommendation |
| Starting dose | 1 drop of 1% solution once daily initially if concerns about systemic beta-blockade |
| Titration | Slower titration; assess tolerance before increasing to twice-daily dosing |
| Special considerations | Increased sensitivity to systemic beta-blocking effects; higher risk of bradycardia and orthostatic hypotension, especially with concurrent oral antihypertensives |
| Monitoring | Pulse rate and blood pressure at baseline and follow-up visits |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Risk | Management |
| Systemic beta-blockers (atenolol, metoprolol, propranolol) | Additive beta-blockade; risk of severe bradycardia, hypotension, heart block | Avoid concurrent use or monitor HR/BP closely |
| Verapamil / Diltiazem (especially IV) | Severe bradycardia, AV block, asystole | Avoid concurrent use |
| Digitalis glycosides (digoxin) | Enhanced AV conduction depression; increased bradycardia risk | Monitor pulse; avoid if baseline bradycardia |
| Clonidine (abrupt withdrawal) | Potentiation of rebound hypertension | Discontinue beta-blocker several days before tapering clonidine |
| Class I antiarrhythmics (quinidine, disopyramide, flecainide) | Additive negative inotropic and dromotropic effects | Avoid or use with extreme caution |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Risk | Management |
| Insulin / Oral hypoglycaemics | May mask hypoglycaemia symptoms (tachycardia, tremor) | Counsel patient; monitor blood glucose |
| Amiodarone | Additive bradycardia; potential QT prolongation | Monitor ECG and pulse |
| SSRIs (fluoxetine, paroxetine) | Potential CYP2D6 inhibition increasing systemic beta-blocker levels | Monitor for bradycardia |
| Reserpine | Additive hypotension and bradycardia | Monitor BP and pulse |
| Other topical antiglaucoma agents | Generally safe to combine | Space administration by at least 5 minutes |
COMMON ADVERSE EFFECTS
Ocular:
- Transient burning or stinging on instillation
- Ocular irritation or discomfort
- Foreign body sensation
- Dry eyes
- Blurred vision (transient)
- Conjunctival hyperaemia
Systemic (due to absorption):
- Headache
- Dizziness
- Mild bradycardia (in sensitive individuals)
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Action |
| Severe bradycardia (<45 bpm) or symptomatic heart block | Discontinue immediately; consider atropine if symptomatic |
| Bronchospasm | Discontinue immediately; administer bronchodilator; avoid future beta-blocker use |
| Hypotension (symptomatic) | Withhold drug; supportive care |
| Exacerbation of heart failure | Discontinue; appropriate heart failure management |
| Stevens-Johnson syndrome (rare) | Discontinue permanently; urgent dermatology referral |
| Depression, severe fatigue | Consider discontinuation; psychiatric evaluation if needed |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
IOP measurement (tonometry), visual acuity, pulse rate, respiratory status (if asthma/COPD history or risk factors) |
|
After initiation
|
IOP recheck at 4–6 weeks; pulse rate assessment within 1 week in elderly or patients with cardiovascular disease |
|
Long-term
|
IOP every 3–6 months; visual field assessment annually; periodic pulse and BP monitoring in elderly or multi-drug patients |
BRANDS AVAILABLE IN INDIA
- Ocupress® 1% Eye Drops (Allergan)
- Cartelol® 1% Eye Drops (Sun Pharma)
- Carteolet® Eye Drops
Note: Limited brand availability compared to timolol. Verify current availability with local distributors.
PRICE RANGE (INR)
| Formulation | Approximate Price |
| 1% eye drops (5 mL) | ₹50–₹120 |
- Not confirmed under NPPA price control
- Available through private retail; limited government hospital supply
- Prices vary by brand and region
CLINICAL PEARLS
- Intrinsic sympathomimetic activity (ISA): Carteolol has partial agonist activity, which may result in fewer systemic cardiovascular effects (less bradycardia, less reduction in cardiac output) compared to timolol. Consider in patients concerned about systemic beta-blockade.
- Punctal occlusion is essential: Advise patients to apply gentle pressure over the nasolacrimal duct for 1–2 minutes after instillation to minimize systemic absorption and reduce cardiovascular/respiratory side effects.
- Non-selective agent: Like timolol, carteolol blocks both β1 and β2 receptors; contraindicated in patients with asthma or significant COPD. Betaxolol (β1-selective) is preferred in such cases.
- Switching from timolol: If switching from another ophthalmic beta-blocker, allow approximately 24-hour washout before assessing response to carteolol.
- Diabetic patients: Counsel regarding masked hypoglycaemia symptoms; sweating remains a reliable warning sign.
- Elderly initiation: Consider once-daily dosing initially in elderly patients to minimize systemic exposure, then titrate based on IOP response and tolerability.
TAGS
Carteolol; glaucoma; ocular-hypertension; beta-blocker; ophthalmic; antiglaucoma; non-selective; IOP-lowering; ISA; Schedule-H; asthma-caution
VERSION
RxIndia v1.0 — 14 Feb 2026
REFERENCES
- CDSCO Product Database and Approved Drug Labels
- Indian Pharmacopoeia (IP)
- National Formulary of India (NFI)
- AIIMS Glaucoma Management Protocols
- API Textbook of Medicine (Ophthalmology chapter)
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics (pharmacology reference)
- ICMR Standard Treatment Guidelines
- Indian Journal of Ophthalmology (clinical reviews)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.